Gossamer Bio
Open
$0.36
Prev. Close
$0.36
High
$0.37
Low
$0.36
Market Snapshot
$80.92M
-0.5
-0.26
$114.7M
144
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Gossamer Bio faces a class action lawsuit after an 80% stock drop linked to misleading PROSERA trial results and undisclosed study data.
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Recently from Cashu
Gossamer Bio Incentivizes Talent Acquisition with New Stock Options for Pulmonary Hypertension Treatment
Gossamer Bio's Strategic Incentives for Talent Acquisition in Pulmonary Hypertension Treatment Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies…
Gossamer Bio Boosts Workforce with Stock Options to Attract Top Talent
Gossamer Bio Strengthens Workforce with Stock Option Grants Gossamer Bio, Inc., a clinical-stage biopharmaceutical company specializing in treatments for pulmonary hypertension, announces the approval…
Gossamer Bio Enhances Workforce Strategy Amid Innovations in Pulmonary Hypertension Treatments
Gossamer Bio Advances Talent Acquisition Strategy Amid Clinical Innovations Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, is making strategic moves to strengthen its workforce as it…
Gossamer Bio Invests in Talent Acquisition with Stock Options for New Employees
Gossamer Bio's Commitment to Talent Acquisition in Biopharmaceuticals Gossamer Bio, Inc. is making strides in the biopharmaceutical sector with a focused commitment to developing innovative treatments…